Rapid decompression of anterior intracranial visual pathways with bromocriptine.
Bromocriptine mesylate (2-bromo-alpha-ergocryptine) has proved to be useful in reducing the size of prolactin-secreting pituitary adenomas, but little evidence has accumulated about its effectiveness within the first two weeks of therapy. The patient described herein showed a rapid reduction in the size of the suprasellar extension of a prolactinoma and a dramatic improvement of the primary visual field abnormalities within two weeks of starting bromocriptine therapy. This experience exemplifies the potential use of the drug in acutely decompressing the anterior intracranial visual pathways.
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011388:Prolactin / Q000378:metabolism; D013997:Time Factors; D014794:Visual Fields / Q000187:drug effects; D014795:Visual Pathways / Q000187:drug effects*
D001971:Bromocriptine; D011388:Prolactin